Designed Inhibitors of Insulin-Degrading Enzyme Regulate the Catabolism and Activity of Insulin - Test2 - elhamkhani - TriplyDB

Designed Inhibitors of Insulin-Degrading Enzyme Regulate the Catabolism and Activity of Insulin

Designed Inhibitors of Insulin-Degrading Enzyme Regulate the Catabolism and Activity of Insulin

http://www.wikidata.org/entity/Q27661904

about

Imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, substrate-dependent modulators of insulin-degrading enzyme in amyloid-β hydrolysis Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones Structure based discovery of small molecules to regulate the activity of human insulin degrading enzyme Bridging Type 2 Diabetes and Alzheimer's Disease: Assembling the Puzzle Pieces in the Quest for the Molecules With Therapeutic and Preventive Potential The diabetes-susceptible gene SLC30A8/ZnT8 regulates hepatic insulin clearance Unraveling Alzheimer's: Making Sense of the Relationship between Diabetes and Alzheimer's Disease1 Interleukin-6 increases the expression and activity of insulin-degrading enzyme.Potential Protein Phosphatase 2A Agents from Traditional Chinese Medicine against Cancer.In Silico Identification of Potent PPAR-γ Agonists from Traditional Chinese Medicine: A Bioactivity Prediction, Virtual Screening, and Molecular Dynamics Study.Treatment of rheumatoid arthritis with traditional chinese medicine.Potential mitochondrial isocitrate dehydrogenase R140Q mutant inhibitor from traditional Chinese medicine against cancers In silico investigation of potential mTOR inhibitors from traditional Chinese medicine for treatment of Leigh syndrome Treatment of cardiovascular disease by traditional Chinese medicine against pregnane X receptor In silico investigation of potential TRAF6 inhibitor from traditional Chinese medicine against cancers.In silico investigation of potential pyruvate kinase M2 regulators from traditional Chinese medicine against cancers.Deletion of insulin-degrading enzyme elicits antipodal, age-dependent effects on glucose and insulin tolerance.Potential smoothened inhibitor from traditional Chinese medicine against the disease of diabetes, obesity, and cancer Peptidomics approach to elucidate the proteolytic regulation of bioactive peptides.Mixed dimers of insulin-degrading enzyme reveal a cis activation mechanism Structure-activity relationships of imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, dual binders of human insulin-degrading enzyme.Structures of human CCL18, CCL3, and CCL4 reveal molecular determinants for quaternary structures and sensitivity to insulin-degrading enzyme.An in silico insight into novel therapeutic interaction of LTNF peptide-LT10 and design of structure based peptidomimetics for putative anti-diabetic activity.Endurance training inhibits insulin clearance and IDE expression in Swiss mice.Dual Exosite-binding Inhibitors of Insulin-degrading Enzyme Challenge Its Role as the Primary Mediator of Insulin Clearance in Vivo.Catalytic site inhibition of insulin-degrading enzyme by a small molecule induces glucose intolerance in mice Modulation of insulin degrading enzyme activity and liver cell proliferation Elevated glucose and oligomeric β-amyloid disrupt synapses via a common pathway of aberrant protein S-nitrosylation.Crystal Structure and Function of PqqF Protein in the Pyrroloquinoline Quinone Biosynthetic Pathway.Brain signaling systems in the Type 2 diabetes and metabolic syndrome: promising target to treat and prevent these diseases.Bioinformatic approaches for predicting substrates of proteases.Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer's disease?Proteolytic degradation of amyloid β-protein.Amyloid-clearing proteins and their epigenetic regulation as a therapeutic target in Alzheimer's disease.Targeting Insulin-Degrading Enzyme to Treat Type 2 Diabetes Mellitus Inhibition of Insulin-Degrading Enzyme Does Not Increase Islet Amyloid Deposition in Vitro Insulin-degrading enzyme: new therapeutic target for diabetes and Alzheimer's disease?Constitutive α- and β-secretase cleavages of the amyloid precursor protein are partially coupled in neurons, but not in frequently used cell lines.Inositol phosphates and phosphoinositides activate insulin-degrading enzyme, while phosphoinositides also mediate binding to endosomes.Hepatic ZIP14-mediated Zinc Transport Contributes to Endosomal Insulin Receptor Trafficking and Glucose Metabolism.Han ethnicity-specific type 2 diabetic treatment from traditional Chinese medicine?

P2860

Q27683399-0CE15CDD-9A42-4A69-9693-92F9DE86DD19 Q27683870-31395EDD-19DA-470F-B6C7-E347AAC71D70 Q28480725-0F9CA0A8-66C9-4C1F-B513-ED6B97C32D27 Q29994589-62922232-EB4F-4159-BD48-D7570E38A439 Q30547080-605D7507-D8AE-44A4-AF1D-9E21E61F11E0 Q33362745-663F1A3E-9B9B-4929-9DF8-AD6997E4695B Q33587718-9B89B9A6-CC39-4390-BDB7-847830798CAF Q33608964-6F247C22-0A4F-4E41-B178-FDC6D82F06B2 Q33757779-D88318E5-6AA6-4F99-AE2C-B8D48B9ED540 Q33786655-3BF59BF5-A5F0-4494-A9D7-7846FB493A35 Q33790946-9D11F7D2-D18F-43E9-A287-88C71DEDDE0F Q33876312-BB956DCE-2BFE-4274-8FD2-D9A6E607D5D6 Q33876600-F8E75C62-A908-49E8-B37F-8B6104CFE362 Q33893880-1CA9DC62-1C40-4430-ACF6-C7F3C6C7C89F Q33895166-1FD663F9-5E41-4B77-8F88-621E520BE689 Q33939720-E1722FD8-CA56-41F4-BBE8-84F0A4EB88A6 Q34022289-CB87347E-A7B9-425F-AE56-9345F597350B Q34268925-14E33AB0-1D59-4B7E-B1ED-15362DC46BA6 Q34799851-16BB91D4-952B-4E77-BF7F-29C409E82693 Q35075464-75798541-4DC6-466F-92DF-AD1B817B87E4 Q35164366-5B7146C8-AECF-4D41-BE92-915090D9DB94 Q35588738-F8988EF4-F7AE-4AA4-A289-0E5801C44294 Q35589856-77A267E0-51C4-489D-BBF9-D86E12BD645E Q35953055-F4D73A6E-36B6-4EF1-BABA-53CAC3CE1775 Q36087916-50498E13-B029-4F6A-A4AD-9D56469C8801 Q36185047-9444D8BE-70A2-42FD-A882-2A0FE2F7D5B5 Q36511191-2632B019-C909-47E3-9F6B-39A818449854 Q37117280-EA3351FA-01C7-461A-A413-F145E8938593 Q37474214-04FBB963-FCF7-46C1-8DCA-062956808C29 Q37844034-62BD913D-8861-4B18-A37E-978F1B5ACA7D Q37961852-19321197-4383-4702-9A8B-4DF7E10995C3 Q38016899-D9FAADFD-A831-4AC7-96DB-3404065728BD Q38256360-EBF16DE2-A82C-4377-9ED6-238D4A6F7B6A Q38664408-63AA1E10-3BF7-4E61-91A2-07C14F753A59 Q38758608-E1362DBD-B240-4639-B1B7-2FE9361D3BD7 Q38869928-4C468573-4697-4A20-87E8-B2F189D5601F Q39287009-E8D46244-B02C-4427-8C16-AC751DC62EE3 Q41826610-9613F965-4080-43D2-B6A6-903589007613 Q43869615-F039980A-628B-4610-9410-6AFF95995CA6 Q44806080-D4929844-38CC-4EAE-A1D2-5DEDDBADA917

P2860

Designed Inhibitors of Insulin-Degrading Enzyme Regulate the Catabolism and Activity of Insulin

http://www.wikidata.org/entity/Q27661904

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Designed Inhibitors of Insulin ...... bolism and Activity of Insulin

@ast

Designed Inhibitors of Insulin ...... bolism and Activity of Insulin

@en

Designed Inhibitors of Insulin ...... bolism and Activity of Insulin

@nl

type

label

Designed Inhibitors of Insulin ...... bolism and Activity of Insulin

@ast

Designed Inhibitors of Insulin ...... bolism and Activity of Insulin

@en

Designed Inhibitors of Insulin ...... bolism and Activity of Insulin

@nl

altLabel

Designed inhibitors of insulin ...... bolism and activity of insulin

@en

prefLabel

Designed Inhibitors of Insulin ...... bolism and Activity of Insulin

@ast

Designed Inhibitors of Insulin ...... bolism and Activity of Insulin

@en

Designed Inhibitors of Insulin ...... bolism and Activity of Insulin

@nl

P1433

Q27661904-2D4ED7FB-EC66-483A-B48B-1CE00E14062F

P1476

Q27661904-D296FDDF-90C5-4CE7-9B79-BF2BD1B6D379

P2093

Q27661904-01161E94-8FCF-4D52-A39B-0029E2BF57F4

Q27661904-025D1E7B-A050-4416-8EDE-46A49B8B6D20

Q27661904-0FFF6ED0-05B8-433B-821C-A89408DE7A10

Q27661904-222F12EC-72B8-47C9-83C5-7CFF86A8ED16

Q27661904-3751353B-0441-4A27-9207-D653339A9DF2

Q27661904-3F9DE67E-E5F5-4817-B96B-FA9AA32F492A

Q27661904-51EAFF2C-6E45-46BA-9CB5-EB6C3337D09F

Q27661904-666E1683-BB47-457B-9F05-A7242D69C5EE

Q27661904-A861BE0F-D085-4BC0-85E6-7ABCC75D1E86

Q27661904-AEB0B941-30F1-4CB9-A5BE-7E6FC0F84200

P2860

Q27661904-1108C390-BACD-486A-82E3-8D3DCEC36E8D

Q27661904-1C417A6D-F9AE-4502-8D4F-47CE03F46A0F

Q27661904-1EAA6F1A-E435-427E-AAD3-42EF464AB87A

Q27661904-211B447A-107B-4886-AFA0-8BAC6940B234

Q27661904-2465C171-35E6-4D44-9538-0E993C49EF26

Q27661904-254EA511-18C1-4824-B3FC-BB31B6F4D782

Q27661904-2782E36D-72E4-4ACD-A1B3-28BAE66E0178

Q27661904-29867220-27DF-4092-B60A-E46007814732

Q27661904-3AFD09E0-C92B-4E2F-BFF0-EB4839BC8514

Q27661904-3C0761AA-ED2C-4A34-8A62-4A8E75A1D784

P304

Q27661904-EBDA47DD-7795-4958-8863-46E3C47A1BE5

P31

Q27661904-EEEE4316-ABC1-48B9-B9C3-D8332A4306B8

P356

Q27661904-0EFC49FB-30BE-449A-B3E4-F5255488EF19

P407

Q27661904-F31354BA-8C72-490D-ACF1-A23FC80ACE5B

P433

Q27661904-E2783AD8-6284-4370-953A-F309EDF0FF23

P478

Q27661904-E3C747F7-D83F-4AC8-80DD-0845726ABDF8

P50

Q27661904-20B0B2B8-CC33-4C1F-84BA-55A4662F6DC2

Q27661904-6F26DB5E-291F-41BA-A20B-153A4BCCC96A

Q27661904-E10C395C-7020-41AB-B727-65EF8454C680

P577

Q27661904-D14048D1-C636-4E57-91D9-443162EEBDE0

P5875

Q27661904-E6CA6469-D9EA-4037-8E54-7B1CF973000D

P698

Q27661904-04D2A42D-A6A4-42C7-AC0D-90D69DA4C21D

P921

Q27661904-81A6A0BF-2632-4CC9-B657-C50061EFEF8E

P932

Q27661904-28A79A66-8586-42CC-8ED1-E527EA2FCA38

P356

JOURNAL.PONE.0010504

P1433

P1476

Designed Inhibitors of Insulin ...... bolism and Activity of Insulin

@en

P2093

Abdul H Fauq

http://www.w3.org/2001/XMLSchema#string

Benjamin E Turk

http://www.w3.org/2001/XMLSchema#string

Dennis J Selkoe

http://www.w3.org/2001/XMLSchema#string

Enrico Malito

http://www.w3.org/2001/XMLSchema#string

Ghulam M Maharvi

http://www.w3.org/2001/XMLSchema#string

Gregory D Cuny

http://www.w3.org/2001/XMLSchema#string

Lael Reinstatler

http://www.w3.org/2001/XMLSchema#string

Malcolm A Leissring

http://www.w3.org/2001/XMLSchema#string

Malwina Huzarska

http://www.w3.org/2001/XMLSchema#string

Marika Manolopoulou

http://www.w3.org/2001/XMLSchema#string

P2860

Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism

Structure of substrate-free human insulin-degrading enzyme (IDE) and biophysical analysis of ATP-induced conformational switch of IDE

Molecular basis for the thiol sensitivity of insulin-degrading enzyme

Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo

Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination

Processing of X-ray diffraction data collected in oscillation mode

Molecular Bases for the Recognition of Short Peptide Substrates and Cysteine-Directed Modifications of Human Insulin-Degrading Enzyme †

Molecular Basis of Catalytic Chamber-assisted Unfolding and Cleavage of Human Insulin by Human Insulin-degrading Enzyme

Coot: model-building tools for molecular graphics

Phasercrystallographic software

P304

e10504

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0010504

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Lewis C. Cantley

Sabrine Hédouin

P577

2010-05-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44626710

http://www.w3.org/2001/XMLSchema#string

P698

20498699

http://www.w3.org/2001/XMLSchema#string

P921

P932

2866327

http://www.w3.org/2001/XMLSchema#string